A single infusion of a patient's own blood cells coupled with seven myelin peptides was safe and well-tolerated in MS patients, and higher doses reduced the immune attack against myelin.
7 myelin peptides on one cell infusionA single treatment simultaneously targeted seven different myelin protein fragments that the immune system attacks in multiple sclerosis
What the researchers found
All nine patients tolerated the peptide-coupled cell infusion without serious adverse events. Patients receiving higher doses (more than 1 billion peptide-coupled cells) showed a measurable decrease in T cell reactivity against the myelin peptides used in the therapy.
This is significant because it suggests the treatment achieved its intended mechanism — reducing the specific immune response against myelin without broadly suppressing immunity. The therapy was feasible to manufacture from each patient's own blood cells and the seven myelin peptides covered multiple autoimmune targets simultaneously.
Why it matters
Current MS treatments broadly suppress the immune system, which controls the disease but leaves patients vulnerable to infections and cancers. Antigen-specific tolerance — teaching the immune system to stop attacking just the myelin targets — would be a paradigm shift, treating the root cause while leaving the rest of immunity intact. This trial is the first demonstration that this approach is feasible and safe in human MS patients.
The numbers in context
n=9; 7 myelin peptides; doses up to >1×10⁹ cells; decreased T cell reactivity at higher doses
How the study worked
Open-label, single-center, dose-escalation phase 1 trial. Nine MS patients (7 relapsing-remitting, 2 secondary progressive) off standard therapies received a single intravenous infusion of their own blood cells chemically coupled with seven myelin peptides. Safety, tolerability, and immune responses were monitored through neurological exams, MRI, laboratory tests, and immunological assessments.
Who was studied
Nine adult MS patients (7 relapsing-remitting, 2 secondary progressive), off standard therapies, with confirmed T cell reactivity against at least one of the target myelin peptides
What this study cannot tell us
Phase 1 safety trial only; n=9; no control group; open-label; single center; patients off standard therapy; clinical efficacy not assessed; long-term durability unknown.
How to read the evidence
This is a phase 1, first-in-human, open-label dose-escalation trial with only 9 patients and no control group. While published in the high-impact journal Science Translational Medicine, its small size and safety-focused design provide only preliminary clinical evidence.
When this study was published
Published in 2013, this was a groundbreaking first-in-human proof of concept. The approach has since advanced into larger trials, and the field of antigen-specific tolerance for autoimmune disease has continued to evolve.
The bigger picture
This trial is part of a broader effort to develop antigen-specific immunotherapy for autoimmune diseases. The concept — using peptide-coupled cells to induce tolerance — was proven in animal models of MS decades ago and this was the critical first step into humans. If effective in larger trials, this approach could potentially apply not just to MS but to other autoimmune conditions like type 1 diabetes, where the immune targets are known.
Questions still open
- Does the reduction in myelin-specific T cell reactivity translate to fewer MS relapses or slower disease progression?
- Could repeated infusions of peptide-coupled cells provide sustained tolerance, or is the effect temporary?
- Can this antigen-specific tolerance approach work in patients already on standard MS immunotherapies?
Common questions
How is this different from current MS treatments?
Is this treatment available for MS patients now?
Read the original research
Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis.
Science translational medicine, 5(188), 188ra75
Citation
Lutterotti, Andreas; Yousef, Sara; Sputtek, Andreas; Stürner, Klarissa H; Stellmann, Jan-Patrick; Breiden, Petra; Reinhardt, Stefanie; Schulze, Christian; Bester, Maxim; Heesen, Christoph; Schippling, Sven; Miller, Stephen D; Sospedra, Mireia; Martin, Roland. (2013). Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis.. Science translational medicine, 5(188), 188ra75. https://doi.org/10.1126/scitranslmed.3006168